The Journey of Omeprazole

Omeprazole is a benzimidazole prodrug that is chemically unstable
at low pH. At gastric pH (1-2), the drug degrades rapidly before it can be absorbed. Therefore,
all oral formulations are enteric-coated to delay dissolution until the drug reaches the neutral
environment of the small intestine (pH 5.5-7). Once the coating dissolves, omeprazole is rapidly
absorbed from the proximal small intestine. Oral bioavailability is 30-40% after a single dose
and increases to 60-65% with repeated dosing because omeprazole itself raises gastric pH, reducing
acid degradation of subsequent doses that escape enteric coating. Peak plasma concentration occurs
1-3 hours post-dose. Taking omeprazole 30-60 minutes before a meal is important because acid
secretion triggered by eating provides the acidic milieu needed for the prodrug to be converted
to its active form within parietal cell canaliculi.

After intestinal absorption, omeprazole enters portal circulation
and is rapidly taken up by the liver. It is approximately 95% bound to plasma albumin and alpha-1-
acid glycoprotein. Its volume of distribution is modest (0.3 L/kg). The drug reaches the parietal
cells of the gastric fundus through the systemic circulation. Crucially, omeprazole undergoes
selective concentration within the acidic lumen of parietal cell secretory canaliculi (pH 1-2),
where its concentration can be 1,000-fold higher than plasma. This selective accumulation is the
key to the drug's tissue selectivity — no other cell type in the body maintains such an acidic
intracellular compartment, making the proton pump an exquisitely selective pharmacological target.

In the acidic canalicular lumen, omeprazole (pKa 4.0) is protonated
and undergoes acid-catalyzed conversion to a sulfenamide (actually a sulfenic acid intermediate
that rearranges). This reactive intermediate forms covalent disulfide bonds with cysteine residues
on the luminal surface of the H+/K+-ATPase (proton pump) — most importantly Cys813 and Cys892 of
the alpha subunit. This covalent modification is irreversible under physiological conditions.
Because the reaction requires acid, it occurs specifically and almost exclusively within parietal
cell secretory canaliculi. The inactivated pump can be partially reactivated in vivo by glutathione,
but functional acid secretion is restored primarily by synthesis of new H+/K+-ATPase molecules
(half-life ~18 hours). A single dose of omeprazole achieves 70-80% inhibition of acid secretion;
maximal inhibition requires 3-5 days of once-daily dosing to reach steady state.

Omeprazole is extensively metabolized by hepatic cytochrome P450
enzymes, primarily CYP2C19 (major) and CYP3A4 (minor). CYP2C19 produces the principal metabolite,
5-hydroxyomeprazole, while CYP3A4 generates the sulfone. Both metabolites are pharmacologically
inactive. CYP2C19 shows clinically important genetic polymorphism: approximately 2-5% of
Caucasians and 12-20% of East Asians are poor metabolizers (homozygous CYP2C19 loss-of-function
variants), resulting in 5-10-fold higher omeprazole plasma concentrations and substantially greater
acid suppression compared to extensive metabolizers. Intermediate metabolizers show intermediate
plasma exposures. This pharmacogenomic variability is clinically relevant — poor metabolizers
achieve H. pylori eradication rates 10-20% higher with omeprazole-based triple therapy. Drug
interactions involving CYP2C19 inhibition (fluconazole, fluvoxamine) can substantially increase
omeprazole exposure.

The hydroxy and sulfone metabolites of omeprazole are further
conjugated (glucuronidation) and excreted primarily in urine (approximately 80%) with the
remainder in feces via biliary secretion. The plasma half-life of omeprazole is short (0.5-1 hour),
but pharmacodynamic effects persist for 18-24 hours because the drug's action is irreversible —
the duration of acid suppression is determined by the rate of new H+/K+-ATPase synthesis, not
by the drug's plasma half-life.

PPIs are the most effective drugs for acid-related disorders.
Long-term use (> 1 year) raises concerns about hypomagnesemia, vitamin B12 deficiency, increased
susceptibility to Clostridioides difficile and enteric infections, and possible interactions
with clopidogrel (CYP2C19 competition). The clopidogrel interaction is debated — prospective
trials did not confirm the observational mortality signal. Rebound acid hypersecretion upon
abrupt PPI discontinuation can cause symptomatic rebound for 2-4 weeks due to parietal cell
hyperplasia during prolonged suppression.